|
Mechanismgalectin-3 inhibitors |
Active Org.- |
Originator Org.- |
Active Indication- |
|
Drug Highest PhaseDiscontinued |
First Approval Ctry. / Loc.- |
First Approval Date- |
/ CompletedNot Applicable A phase II study of GCS-100 in combination with chemo-immunotherapy in relapsed or refractory diffuse large B-cell lymphoma
/ Unknown statusNot Applicable A Phase 2 Study of GCS-100 in Combination with Chemo-immunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
100 Clinical Results associated with Prospect Therapeutics, Inc.
0 Patents (Medical) associated with Prospect Therapeutics, Inc.
100 Deals associated with Prospect Therapeutics, Inc.
100 Translational Medicine associated with Prospect Therapeutics, Inc.